| NCT04364893 |
Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID-19 (BRACE-CORONA) |
Hospitalized, COVID-19 (∼700 subjects) |
ACEi and ARBs |
Recruiting |
| NCT04335136 |
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19) |
Hospitalized, COVID-19 (200 subjects) |
RhACE2, APN01 |
Recruiting |
| NCT04321096 |
The Impact of Camostat Mesilate on COVID-19 Infection (CamoCO-19) |
Hospitalized, COVID-19 (580 subjects) |
Camostat Mesilate |
Recruiting |
| NCT04338009 |
Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 (REPLACECOVID) |
Hospitalized, COVID-19 (152 subjects) |
ARB/ACEi |
Recruiting |
| NCT04312009 |
Losartan for Patients With COVID-19 Requiring Hospitalization |
Hospitalized, COVID-19 (200 subjects) |
Losartan |
Recruiting |
| NCT04311177 |
Losartan for Patients With COVID-19 Not Requiring Hospitalization |
Patients with COVID-19 (580 subjects) |
Losartan |
Active, not Recruiting |
| NCT04318418 |
ACE Inhibitors, Angiotension II Type-I Receptor Blockers and Severity of COVID-19 (CODIV-ACE) |
Hospitalized, COVID-19 (3400 subjects) |
ACEi and ARBs |
Completed |
| NCT04315298 |
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 |
Hospitalized, COVID-19 (1912 subjects) |
Sarilumab |
Completed |
| NCT04320615 |
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) |
Hospitalized, severe COVID-19 Pneumonia (450 subjects) |
Tocilizumab (TCZ) |
Completed |
| NCT04330638 |
Treatment of COVID-19 Patients With Anti-interleukin Drugs (COV-AID) |
Hospitalized, CIVID-19 with systemic cytokine release syndrome (342 subjects) |
Anakinra Siltuximab Tocilizumab |
Recruiting |
| NCT04322188 |
An Observational study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications (SISCO) |
Hospitalized, ARDS, secondary to SARS-COV-2 Infection (220 subjects) |
Siltuximab (SYLVANT) |
Completed |
